AR028196A1 - Composicion - Google Patents

Composicion

Info

Publication number
AR028196A1
AR028196A1 ARP010100121A ARP010100121A AR028196A1 AR 028196 A1 AR028196 A1 AR 028196A1 AR P010100121 A ARP010100121 A AR P010100121A AR P010100121 A ARP010100121 A AR P010100121A AR 028196 A1 AR028196 A1 AR 028196A1
Authority
AR
Argentina
Prior art keywords
compound
ring
hydrocarbyl
group
composition
Prior art date
Application number
ARP010100121A
Other languages
English (en)
Original Assignee
Sterix Ltd
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0000792A external-priority patent/GB0000792D0/en
Priority claimed from GB0002115A external-priority patent/GB0002115D0/en
Application filed by Sterix Ltd, Schering Ag filed Critical Sterix Ltd
Publication of AR028196A1 publication Critical patent/AR028196A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Confectionery (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se presenta una composicion farmacéutica que comprende (i) un compuesto de la formula (I) en la cual: X es un anillo de hidrocarbilo con por lo menos 4 átomos en el anillo, K es un grupo hidrocarbilo, Rs es un grupo sulfamato, (ii) optativamente me zclado con un vehículo, diluyente, excipiente o adyuvante farmacéuticamente aceptable, donde el compuesto está presente en una cantidad que produce una dosis de no más de 200 mug/ día.
ARP010100121A 2000-01-14 2001-01-11 Composicion AR028196A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0000792A GB0000792D0 (en) 2000-01-14 2000-01-14 Composition
GB0002115A GB0002115D0 (en) 2000-01-28 2000-01-28 Composition
US21873000P 2000-07-17 2000-07-17

Publications (1)

Publication Number Publication Date
AR028196A1 true AR028196A1 (es) 2003-04-30

Family

ID=27255470

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010100121A AR028196A1 (es) 2000-01-14 2001-01-11 Composicion

Country Status (26)

Country Link
EP (1) EP1248626B1 (es)
JP (1) JP2003519658A (es)
KR (1) KR20020087930A (es)
CN (1) CN1404394A (es)
AR (1) AR028196A1 (es)
AT (1) ATE332140T1 (es)
AU (1) AU2533101A (es)
BG (1) BG106914A (es)
BR (1) BR0107630A (es)
CA (1) CA2396098A1 (es)
CO (1) CO5280199A1 (es)
CZ (1) CZ20022282A3 (es)
DE (1) DE60121293T2 (es)
EE (1) EE200200391A (es)
ES (1) ES2267707T3 (es)
HR (1) HRP20020665A2 (es)
HU (1) HUP0300887A2 (es)
IL (1) IL150471A0 (es)
MX (1) MXPA01000464A (es)
NO (1) NO20023392L (es)
PE (1) PE20011121A1 (es)
PL (1) PL357020A1 (es)
SK (1) SK10022002A3 (es)
TR (1) TR200100070A3 (es)
UY (1) UY26530A1 (es)
WO (1) WO2001051055A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10027887A1 (de) * 2000-05-31 2001-12-13 Jenapharm Gmbh Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
GB0020498D0 (en) 2000-08-18 2000-10-11 Sterix Ltd Compound
GB0025788D0 (en) * 2000-10-20 2000-12-06 Sterix Ltd Use
EP1358882A1 (en) * 2002-04-30 2003-11-05 Schering Aktiengesellschaft Use of estriol sulfamate prodrugs for the treatment of autoimmune diseases
US7534780B2 (en) 2004-05-21 2009-05-19 Bayer Schering Pharma Aktiengesellschaft Estradiol prodrugs
KR200449618Y1 (ko) * 2008-01-16 2010-07-23 주식회사 코비스 스포츠 그린보수기
GB201302368D0 (en) * 2013-02-11 2013-03-27 Univ Bath Compound
US11253498B2 (en) * 2017-06-01 2022-02-22 Nexyon Biotech Co., Ltd. Pharmaceutical composition for treatment of bone-related disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5556847A (en) * 1994-10-27 1996-09-17 Duquesne University Of The Holy Ghost Methods of effecting memory enhancement mediated by steroid sulfatase inhibitors
US5891868A (en) * 1997-11-21 1999-04-06 Kaiser Foundation Health Plan, Inc. Methods for treating postmenopausal women using ultra-low doses of estrogen

Also Published As

Publication number Publication date
EE200200391A (et) 2003-12-15
CZ20022282A3 (cs) 2002-11-13
AU2533101A (en) 2001-07-24
NO20023392L (no) 2002-09-16
BR0107630A (pt) 2002-10-08
PL357020A1 (en) 2004-07-12
HUP0300887A2 (hu) 2003-07-28
WO2001051055A3 (en) 2002-03-21
SK10022002A3 (sk) 2002-12-03
PE20011121A1 (es) 2001-11-05
DE60121293D1 (de) 2006-08-17
HRP20020665A2 (en) 2004-12-31
TR200100070A2 (tr) 2001-08-21
JP2003519658A (ja) 2003-06-24
CN1404394A (zh) 2003-03-19
CO5280199A1 (es) 2003-05-30
BG106914A (en) 2003-01-31
WO2001051055A2 (en) 2001-07-19
ES2267707T3 (es) 2007-03-16
EP1248626B1 (en) 2006-07-05
IL150471A0 (en) 2002-12-01
EP1248626A2 (en) 2002-10-16
ATE332140T1 (de) 2006-07-15
KR20020087930A (ko) 2002-11-23
DE60121293T2 (de) 2007-06-28
TR200100070A3 (tr) 2001-08-21
MXPA01000464A (es) 2003-07-21
NO20023392D0 (no) 2002-07-12
UY26530A1 (es) 2001-07-31
CA2396098A1 (en) 2001-07-19

Similar Documents

Publication Publication Date Title
YU53402A (sh) Preparat
ITRM920155A0 (it) Composizione farmaceutica contenente 3-2 (dimetilammino) etil-n-metil-1h-indol-5-metansolfonammide, e relativo procedimento di preparazione e trattamento con essa di mammiferi.
AR033859A1 (es) Inhibidores de la metaloproteinasa de la matriz
PT102548A (pt) Formulacao farmaceutica para administracao por injeccao do composto 7alfa-¬9-(4,4,5,5,5-pentafluoropentilsulfinil)-nonil| estra-1,3,5(10)-trieno-3,17beta-diol (fulvestrant)
ES2159491A1 (es) Base cristalina de citalopram
LT2003017A (en) Polymorphs of an epothilone analog
DE60019693D1 (de) Pharmazeutische zusammensetzungen, die wirkstoffabsorptionsfördernde verbindungen enthalten
ATE303149T1 (de) Orale pharmazeutische zusammensetzung aus cefpodoxim-proxetil
WO2004032909A3 (en) Stabilized pharmaceutical composition containing basic excipients
GT199900154A (es) Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.
DK0733046T3 (da) Benzoylguanidiner, deres fremstilling og anvendelse i medikamenter
AR027360A1 (es) Composicion farmaceutica
ES2181366T3 (es) Derivados de piperidina que tienen efectos sobre sistemas relacionados con serotonina.
BR0212353A (pt) Composto, composição farmacêutica, e, uso de um composto
EA200000431A2 (ru) Новые замещенные димерные соединения, способ их получения и фармацевтические композиции, содержащие их
UY26530A1 (es) Composición.
UY26678A1 (es) El uso de composiciones a base de antibióticos de azalidos para tratar o prevenir una infección bacteriana o protozoaria en mamíferos
BR9915692A (pt) Monohidrato de bromidrato de eletriptano
DK0701449T3 (da) Fremgangsmåde til fremstilling af en oral fast dosisform indeholdende diclofenac
PT1463504E (pt) Composicoes compreendendo epotilonas e sua utilizacao para o tratamento de sindroma carcinoide
MX9401171A (es) Forma purificada de estreptograminas, procedimiento para su preparacion y composiciones farmaceuticas que las contienen.
AR014539A1 (es) Derivados de 5'-desoxicitidina, una composicion farmaceutica y kit que los comprende, el uso de los mismos para la fabricacion de un medicamento
ATE445589T1 (de) Neue retinoidderivate und eine pharmazeutische anti-krebs-zusammensetzung, die diese verbindungen enthält
ES2194412T3 (es) Uso de derivados de hidantoina para la preparacion de un medicamento para el tratamiento de vasculitis resistente al tratamiento.
ES2170649B1 (es) Uso de la cdp-colina en el tratamiento de la abstinencia alcoholica.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal